Shots:

• Takeda will divest a portfolio of ~18 select OTC and prescription pharmaceutical assets including Neosaldina- Nesina- and Dramin sold in Brazil- Mexico- Argentina- Colombia- Ecuador- Panama and Peru to Hypera for a total value ~$825M. The transaction is expected to be close in H2’20
• Takeda expects that its ~300 employees supporting the divested assets will be given the opportunity to transition over to Hypera. Additionally- Takeda and Hypera Pharma signed a manufacturing & supply agreement under which Takeda will manufacture the products and supply them to Hypera
• The divestiture marks Takeda’s fifth divestment over the last 12mos. and allow the company to focus on its key areas by simplifying its portfolio

Click here ­to­ read full press release/ article 

 Ref: Takeda | Image:Takeda